[Good news about pulmonary hypertension]

Arch Bronconeumol. 2001 Mar;37(3):105-7. doi: 10.1016/s0300-2896(01)75030-2.
[Article in Spanish]
No abstract available

MeSH terms

  • Anticoagulants / therapeutic use
  • Bone Morphogenetic Protein Receptors, Type II
  • Calcium Channel Blockers / therapeutic use
  • Chromosomes, Human, Pair 2 / genetics
  • Endothelium, Vascular / pathology
  • Epoprostenol / administration & dosage
  • Epoprostenol / adverse effects
  • Epoprostenol / therapeutic use
  • Genetic Predisposition to Disease
  • Humans
  • Hypertension, Pulmonary* / classification
  • Hypertension, Pulmonary* / drug therapy
  • Hypertension, Pulmonary* / epidemiology
  • Hypertension, Pulmonary* / etiology
  • Hypertension, Pulmonary* / genetics
  • Hypertension, Pulmonary* / pathology
  • Muscle, Smooth, Vascular / pathology
  • Mutation
  • Prevalence
  • Protein Serine-Threonine Kinases / deficiency
  • Protein Serine-Threonine Kinases / genetics*
  • Survival Analysis
  • World Health Organization

Substances

  • Anticoagulants
  • Calcium Channel Blockers
  • Epoprostenol
  • Protein Serine-Threonine Kinases
  • BMPR2 protein, human
  • Bone Morphogenetic Protein Receptors, Type II